PSOH

During a live event, Kathleen A. Dorritie, MD, discussed updated outcomes from the IsKia, MASTER, and CONCEPT clinical trials of frontline therapy in multiple myeloma.

During a live event, Kathleen A. Dorritie, MD, discussed updated outcomes from the GRIFFIN and PERSEUS clinical trials of quadruplet therapy in multiple myeloma.

In an interview with Targeted Oncology, Arturo Loaiza-Bonilla, MD, MSEd, discussed the growing use of artificial intelligence in oncology practices. Loaiza-Bonilla is a medical oncologist and cofounder of Massive Bio, a company that uses AI to connect oncologists and patients with cancer to clinical trials of novel treatments.

In an interview with Targeted Oncology for Esophageal Cancer Awareness Month, Arturo Loaiza-Bonilla, MD, MSEd, discussed the pressing need to keep up with the developments in targeted therapies for esophageal and GEJ cancers.

PSOH gives its congratulations to Edward Balaban, DO, FACP, FASCO and Marilyn Heine, MD for being awarded at the ASCO Advocacy Summit.

The paradigm for management of relapsed myeloma is evolving rapidly with a plethora of treatment options based on results of clinical trials. One explosive area of scientific and clinical research is the investigation of chimeric antigen receptor T-cell therapy.

Coronavirus disease 2019 has disrupted oncologic care across the spectrum of cancer screening, diagnosis, and management.

Targeted Oncology, a multimedia resource that offers engaging content and expert opinions on standard and emerging treatments in the field of oncology, has added the Pennsylvania Society of Oncology and Hematology to its Strategic Alliance Partnership program.

Arturo Loaiza-Bonilla, MD, MSEd, FACP ascended to the presidency of the Pennsylvania Society of Oncology, albeit virtually, during the society’s Annual Scientific Conference held via ZOOM on September 25.